Related Experiment Video
Updated: Jul 17, 2026
09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
Glucoindole alkaloids from Ophiorrhiza acuminata
Planta Medica
|June 1, 1995
Summary
Researchers extracted harman, lyalosidic acid, and palicoside from Ophiorrhiza acuminata L. leaves. Their structures were confirmed using 2D-NMR spectroscopy and literature comparisons, validating these compounds in the plant.
Area of Science:
- Phytochemistry: Investigating the chemical constituents of medicinal plants.
- Natural Product Chemistry: Isolation and structural elucidation of bioactive compounds.
Background:
- Ophiorrhiza acuminata L. is a plant species known for its potential medicinal properties.
- Previous research on Ophiorrhiza species suggests the presence of various bioactive alkaloids and glycosides.
Discussion:
- The study successfully isolated and identified three key compounds: harman, lyalosidic acid, and palicoside.
- Structural confirmation was achieved through advanced spectroscopic techniques, specifically 2D-NMR spectroscopy.
- Comparison with existing literature data further validated the identified structures, ensuring accuracy and reliability.
Key Insights:
- Harman, a known beta-carboline alkaloid, was identified in Ophiorrhiza acuminata L. leaves.
- Lyalosidic acid and palicoside, likely glycosidic compounds, represent significant phytochemical discoveries from this plant source.
- The successful isolation and verification highlight the rich chemical profile of Ophiorrhiza acuminata L.
Outlook:
- Further investigation into the biological activities and potential therapeutic applications of these isolated compounds is warranted.
- This research contributes to the chemotaxonomic understanding of the Ophiorrhiza genus.
- Future studies could explore optimized extraction methods and large-scale synthesis of these valuable natural products.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...